186595-68-6

Basic information

• Product Name: tert-butyl 4-(4-fluorobenzoyl)piperazine-1-carboxylate
• Synonyms: tert-butyl 4-(4-fluorobenzoyl)piperazine-1-carboxylate
• CAS NO: 186595-68-6
• Molecular Weight: 308.353
• Mol File: 186595-68-6.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: tert-butyl 4-(4-fluorobenzoyl)piperazine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(4-fluorobenzoyl)piperazine-1-carboxylate(186595-68-6)
• EPA Substance Registry System: tert-butyl 4-(4-fluorobenzoyl)piperazine-1-carboxylate(186595-68-6)

Safety Data

• Hazardous Substances Data: 186595-68-6(Hazardous Substances Data)

Upstream product

• 456-22-4 4-Fluorobenzoic acid 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 403-43-0 4-fluorobenzoyl chloride 

Downstream Products

• 1391636-33-1 C₂₂H₂₄ClFN₂O₃ 
• 1260098-68-7 2-[4-(4-fluoro-benzoyl)-piperazin-1-yl]-1-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-ethanone 
• 102391-98-0 1-(4-fluorobenzoyl)piperazine 
• 1395397-44-0 C₂₆H₂₉F₄N₃O₄ 
• 1537890-85-9 2-{3-[4-(4-fluorobenzoyl)piperazin-1-yl]-3-oxo-propyl}-3H-quinazolin-4-one 
• 477204-95-8 C₁₁H₁₃FN₂O*C₂HF₃O₂ 
• 1622867-12-2 C₂₅H₂₁FN₄O₃S 

Relevant articles and documents

Optimization and SAR research at the piperazine and phenyl rings of JNJ4796 as new anti-influenza A virus agents, part 1

JNJ4796, a small molecule fuse inhibitor targeting the conserved stem region of hemagglutinin, effectively neutralized a broad spectrum of group 1 influenza A virus (IAV), and protected mice against lethal and sublethal influenza challenge after oral admi

N?-Acryloyllysine Piperazides as Irreversible Inhibitors of Transglutaminase 2: Synthesis, Structure-Activity Relationships, and Pharmacokinetic Profiling

Transglutaminase 2 (TGase 2)-catalyzed transamidation represents an important post-translational mechanism for protein modification with implications in physiological and pathophysiological conditions, including fibrotic and neoplastic processes. Consequently, this enzyme is considered a promising target for the diagnosis of and therapy for these diseases. In this study, we report on the synthesis and kinetic characterization of N?-acryloyllysine piperazides as irreversible inhibitors of TGase 2. Systematic structural modifications on 54 new compounds were performed with a major focus on fluorine-bearing substituents due to the potential of such compounds to serve as radiotracer candidates for positron emission tomography. The determined inhibitory activities ranged from 100 to 10?000 M-1 s-1, which resulted in comprehensive structure-activity relationships. Structure-activity correlations using various substituent parameters accompanied by covalent docking studies provide an advanced understanding of the molecular recognition for this inhibitor class within the active site of TGase 2. Selectivity profiling of selected compounds for other transglutaminases demonstrated an excellent selectivity toward transglutaminase 2. Furthermore, an initial pharmacokinetic profiling of selected inhibitors was performed, including the assessment of potential membrane permeability and liver microsomal stability.

HETEROAROMATIC DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF

Disclosed are heteroaryl derivatives, pharmaceutical composition and uses in the manufacture of a medicine for treating respiratory diseases, especially for chronic obstructive pulmonary disease (COPD).